Skip to main content
Atrás
BIOGY logo

BioGaia AB (publ)

Calidad de datos: 100%
Sobrecompra
BIOGY
OTC Healthcare Drug Manufacturers - Specialty & Generic
$11.00
▼ $1.21 (-11.00%)
Cap. Mercado: 1.08B
Rango del Día
$11.00 $11.00
Rango de 52 Semanas
$8.79 $11.46
Volumen
1,000
Promedio 50D / 200D
$10.75 / $10.17
Cierre Anterior
$11.00

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (627 pares)

Métrica Acción Mediana del Sector
P/E 3.3 0.3
P/B 0.8 2.9
ROE % 21.9 3.7
Net Margin % 21.6 3.8
Rev Growth 5Y % 18.3 10.0
D/E 0.0 0.2

Precio Objetivo de Analistas

No hay cobertura de analistas disponible

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2027 $0.00
$0.00 – $0.00
 1.8 B 0
FY2026 $0.00
$0.00 – $0.00
 1.6 B 0

Puntos Clave

Revenue grew 18.31% annually over 5 years — strong growth
ROE of 21.91% indicates high profitability
Net margin of 21.63% shows strong profitability
Debt/Equity of 0.00 — conservative balance sheet
Generating 302.97M in free cash flow
P/E of 3.26 — trading at a low valuation

Crecimiento

Revenue Growth (5Y)
18.31%
Revenue (1Y)8.11%
Earnings (1Y)-5.30%
FCF Growth (3Y)-10.38%

Calidad

Return on Equity
21.91%
ROIC23.54%
Net Margin21.63%
Op. Margin26.82%

Seguridad

Debt / Equity
0.00
Current Ratio6.12
Interest Coverage48.84

Valoración

P/E Ratio
3.26
P/B Ratio0.82
EV/EBITDA0.68
Dividend Yield0.07%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 8.11% Revenue Growth (3Y) 8.92%
Earnings Growth (1Y) -5.30% Earnings Growth (3Y) -4.56%
Revenue Growth (5Y) 18.31% Earnings Growth (5Y) 14.11%
Profitability
Revenue (TTM) 1.54B Net Income (TTM) 332.76M
ROE 21.91% ROA 20.83%
Gross Margin 73.37% Operating Margin 26.82%
Net Margin 21.63% Free Cash Flow (TTM) 302.97M
ROIC 23.54% FCF Growth (3Y) -10.38%
Safety
Debt / Equity 0.00 Current Ratio 6.12
Interest Coverage 48.84 Dividend Yield 0.07%
Valuation
P/E Ratio 3.26 P/B Ratio 0.82
P/S Ratio 0.70 PEG Ratio -5.65
EV/EBITDA 0.68 Dividend Yield 0.07%
Market Cap 1.08B Enterprise Value 282.16M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1.54B 1.42B 1.30B 1.10B 785.11M
Net Income 332.76M 351.39M 365.35M 373.77M 196.27M
EPS (Diluted) 3.29 3.48 3.62 3.70 1.94
Gross Profit 1.13B 1.03B 950.19M 801.93M 582.95M
Operating Income 412.47M 423.37M 443.10M 361.46M 253.74M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.60B 2.03B 2.33B 2.21B 2.13B
Total Liabilities 283.59M 310.07M 302.85M 241.55M 250.69M
Shareholders' Equity 1.31B 1.72B 2.03B 1.97B 1.88B
Total Debt 0.0 29.48M 8.80M 20.09M 10.40M
Cash & Equivalents 801.31M 1.22B 1.54B 1.49B 1.48B
Current Assets 1.22B 1.61B 1.87B 1.80B 1.75B
Current Liabilities 199.14M 206.20M 195.74M 164.99M 126.95M

Puntuaciones de Estrategias

This stock passed the criteria for 7 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#921 of 1052
25
Custom Capital Light Compounder
#157 of 218
30
Custom Deep Value Investing (Seth Klarman)
#772 of 827
14
Growth Price/Sales Ratio Focus (Ken Fisher)
#419 of 618
24
Custom Contrarian Investing (David Dreman)
#273 of 670
36
Value Defensive Investing (Benjamin Graham)
#277 of 709
34
Value Value Investing (Warren Buffett)
#176 of 203
28

Actividad Reciente

Entró Cash Flow Compounder
Mar 24, 2026
Entró Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entró Capital Light Compounder
Mar 24, 2026
Entró Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Entró Contrarian Investing (David Dreman)
Mar 24, 2026
Entró Defensive Investing (Benjamin Graham)
Mar 24, 2026
Entró Value Investing (Warren Buffett)
Mar 24, 2026